Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Viatris Launches RYZUMVI™ 0.75% in the United States
Viatris Inc. announced the commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% in the United States. This treatment is the only FDA-approved eye drop available in the U.S. market designed to reverse pharmacologically-induced mydriasis, commonly caused by adrenergic agonists like…
GRF Releases Audiobook for the Visually Impaired
The Glaucoma Research Foundation (GRF) has recently released a 48-minute audiobook version of their comprehensive 40-page educational guide, “Understanding and Living with Glaucoma.” This project aims to extend the reach of their essential information to those affected by glaucoma, especially…
Aurion’s First Canadian Dose in Corneal Edema Trial
Aurion Biotech has dosed the first Canadian participant in its phase 1/2 clinical trial, known as ABA-1, CLARA. The trial investigates the efficacy and safety of AURN001, a novel cell therapy aimed at treating corneal edema resulting from corneal endothelial…
ABVC BioPharma and ForSeeCon Ink Global Agreement
ABVC BioPharma, Inc. has entered into a significant global licensing agreement with ForSeeCon Eye Corporation (FEYE), marking a pivotal moment for the clinical-stage biopharmaceutical company known for its developments in ophthalmology, CNS, and oncology The agreement focuses on ABVC’s ophthalmology…
Iveric Bio Secures Key J-code for GA Therapy, Izervay
In a significant development for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), Iveric Bio, a subsidiary of Astellas Pharma, has been granted a unique, permanent J-code by the Centers for Medicare & Medicaid Services (CMS) for…
Nanodropper Adaptor Proven Effective in IOP Management
In a pivotal development in the field of ophthalmology, Nanodropper Inc announced that the results from a clinical trial evaluating the Nanodropper® Adaptor have been published in the esteemed journal, Ophthalmology. The study’s findings indicate that there was no clinically…
Scientists Create Enzyme-Activated Healing Contact Lenses
Scientists at the University of Waterloo have made a groundbreaking development in eye care technology by creating a new type of contact lens that not only serves as a protective bandage for corneal wounds but also delivers healing drugs in…
Gene Therapy Aims to Curtail Retinal Degeneration in RP
In a landmark study that promises new hope for nearly 1.5 million people worldwide suffering from retinitis pigmentosa (RP), scientists at Columbia University Vagelos College of Physicians and Surgeons are pioneering a gene therapy that could potentially treat RP patients…
Nicox Reveals Successful Phase 3 Glaucoma Eye Drop
Nicox SA announced the results of its pivotal Mont Blanc Phase 3 trial, which compared the efficacy of its novel nitric oxide-donating bimatoprost eye drop, NCX 470, against latanoprost in reducing intraocular pressure (IOP) in patients suffering from open-angle glaucoma…
2023 Recap: Top 20 Ophthalmic Collaborations of the Year
As we bid farewell to 2023, it’s time to reflect on the remarkable collaborations that have shaped the landscape of ophthalmic innovation. The past year witnessed groundbreaking partnerships between pharmaceutical giants, tech innovators, and research institutions, all aimed at advancing…